These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

628 related items for PubMed ID: 26453247

  • 1. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW, Lynch E.
    Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study.
    Crandell JR.
    Clin Med Insights Cardiol; 2016; 10():123-8. PubMed ID: 27478390
    [Abstract] [Full Text] [Related]

  • 4. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
    Brinton EA, Ballantyne CM, Guyton JR, Philip S, Doyle RT, Juliano RA, Mosca L.
    J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
    [Abstract] [Full Text] [Related]

  • 5. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
    Backes J, Anzalone D, Hilleman D, Catini J.
    Lipids Health Dis; 2016 Jul 22; 15(1):118. PubMed ID: 27444154
    [Abstract] [Full Text] [Related]

  • 6. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.
    Vijayaraghavan K, Szerlip HM, Ballantyne CM, Bays HE, Philip S, Doyle RT, Juliano RA, Granowitz C.
    Postgrad Med; 2019 Aug 22; 131(6):390-396. PubMed ID: 31306043
    [Abstract] [Full Text] [Related]

  • 7. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
    Bazarbashi N, Miller M.
    Expert Rev Cardiovasc Ther; 2020 Apr 22; 18(4):175-180. PubMed ID: 32228246
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
    Ballantyne CM, Bays HE, Philip S, Doyle RT, Braeckman RA, Stirtan WG, Soni PN, Juliano RA.
    Atherosclerosis; 2016 Oct 22; 253():81-87. PubMed ID: 27596132
    [Abstract] [Full Text] [Related]

  • 10. Icosapent ethyl: a review of its use in severe hypertriglyceridemia.
    Kim ES, McCormack PL.
    Am J Cardiovasc Drugs; 2014 Dec 22; 14(6):471-8. PubMed ID: 25428605
    [Abstract] [Full Text] [Related]

  • 11. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.
    Weintraub HS.
    Postgrad Med; 2014 Nov 22; 126(7):7-18. PubMed ID: 25387209
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
    Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.
    Am J Cardiol; 2012 Oct 01; 110(7):984-92. PubMed ID: 22819432
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).
    Mosca L, Ballantyne CM, Bays HE, Guyton JR, Philip S, Doyle RT, Juliano RA.
    Am J Cardiol; 2017 Feb 01; 119(3):397-403. PubMed ID: 27939227
    [Abstract] [Full Text] [Related]

  • 19. Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl.
    Hassan A, Tajuddin N, Shaikh A.
    Cardiol Ther; 2015 Jun 01; 4(1):83-93. PubMed ID: 25515964
    [Abstract] [Full Text] [Related]

  • 20. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ, Zamorano JL, Parhofer KG.
    Pharmacol Ther; 2022 Sep 01; 237():108172. PubMed ID: 35304222
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.